talabostat and Melanoma

talabostat has been researched along with Melanoma* in 2 studies

Reviews

1 review(s) available for talabostat and Melanoma

Article	Year
Talabostat. Expert opinion on investigational drugs, 2007, Volume: 16, Issue:9 Talabostat mesilate is an orally active, specific inhibitor of dipeptidyl peptidases, including tumor-associated fibroblast activation protein. However, by an independent mechanism, talabostat also stimulates the upregulation of cytokines and chemokines to engender a tumor-specific host immune response, thus giving it a unique dual mechanism of action. In clinical trials, talabostat has demonstrated significant activity, including achieving complete responses in patients with non-small-cell lung cancer and malignant melanoma. Topics: Animals; Antineoplastic Agents; Boronic Acids; Carcinoma, Non-Small-Cell Lung; Dipeptides; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Drugs, Investigational; Enzyme Inhibitors; Humans; Melanoma; Pyrrolidines	2007

Article

Year

Expert opinion on investigational drugs, 2007, Volume: 16, Issue:9

Talabostat mesilate is an orally active, specific inhibitor of dipeptidyl peptidases, including tumor-associated fibroblast activation protein. However, by an independent mechanism, talabostat also stimulates the upregulation of cytokines and chemokines to engender a tumor-specific host immune response, thus giving it a unique dual mechanism of action. In clinical trials, talabostat has demonstrated significant activity, including achieving complete responses in patients with non-small-cell lung cancer and malignant melanoma.

Topics: Animals; Antineoplastic Agents; Boronic Acids; Carcinoma, Non-Small-Cell Lung; Dipeptides; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Drugs, Investigational; Enzyme Inhibitors; Humans; Melanoma; Pyrrolidines

2007

Trials

1 trial(s) available for talabostat and Melanoma

Article	Year
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma. BMC cancer, 2009, Jul-30, Volume: 9 Metastatic melanoma is an incurable disease with an average survival of less than one year. Talabostat is a novel dipeptidyl peptidase inhibitor with immunostimulatory properties.. This phase II, open label, single arm study was conducted to evaluate the safety and efficacy of 75-100 mg/m2 cisplatin combined with 300-400 mcg talabostat bid for 6, 21-day cycles. The primary endpoint was overall response. The rate of complete responses, duration of overall objective response, progression-free survival (PFS), and overall survival were the secondary endpoints.. Six objective partial responses were recorded in the 74 patients (8.1%) in the intention-to-treat population. Five of these responses involved the 40 evaluable patients (12.5%). Thirty-one percent of patients reported SAEs to the combination of talabostat and cisplatin.. Acceptable tolerability was observed in the intention-to-treat population and antitumor activity was observed in 12.5% of evaluable patients, which is not greater than historical expectation with cisplatin alone. Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Cisplatin; Dipeptides; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms; Treatment Outcome	2009

Article

Year

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma.

BMC cancer, 2009, Jul-30, Volume: 9

Metastatic melanoma is an incurable disease with an average survival of less than one year. Talabostat is a novel dipeptidyl peptidase inhibitor with immunostimulatory properties.. This phase II, open label, single arm study was conducted to evaluate the safety and efficacy of 75-100 mg/m2 cisplatin combined with 300-400 mcg talabostat bid for 6, 21-day cycles. The primary endpoint was overall response. The rate of complete responses, duration of overall objective response, progression-free survival (PFS), and overall survival were the secondary endpoints.. Six objective partial responses were recorded in the 74 patients (8.1%) in the intention-to-treat population. Five of these responses involved the 40 evaluable patients (12.5%). Thirty-one percent of patients reported SAEs to the combination of talabostat and cisplatin.. Acceptable tolerability was observed in the intention-to-treat population and antitumor activity was observed in 12.5% of evaluable patients, which is not greater than historical expectation with cisplatin alone.

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Cisplatin; Dipeptides; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms; Treatment Outcome

2009